Commentary|Videos|November 21, 2026

ETHAN Trial: Rethinking Endocrine Therapy for Men's Breast Cancer

Fact checked by: Sabrina Serani

Dr Jose Pablo Leone explains how the phase 2 ETHAN trial is testing endocrine therapies in men with breast cancer and why side effects limit adherence.

Endocrine therapy is an important part of care for men with breast cancer, but the options are limited and the side effects can make it hard to stay on treatment. In this video, Jose Pablo Leone, MD, a medical oncologist at the Dana-Farber Cancer Institute and director of the program for breast cancer in men, discusses the phase 2 ETHAN trial (NCT05501704) and how he approaches adherence and adverse events in his patients.

Leone explains that ETHAN is a randomized, multicenter phase 2 trial testing different endocrine therapies in men. It compares tamoxifen (Soltamox) with the aromatase inhibitor anastrozole (Arimidex), given alone and in combination with gonadal suppression. The study aims to answer whether an aromatase inhibitor works on its own or needs gonadal suppression, and whether an aromatase inhibitor with gonadal suppression performs better than tamoxifen alone. ETHAN is also evaluating the addition of the CDK4/6 inhibitor abemaciclib (Verzenio) in men, including whether the backbone endocrine therapy, tamoxifen vs an aromatase inhibitor with gonadal suppression, affects its role.

Leone notes that adherence matters for both men and women, but the side effects differ. Men can have a somewhat higher risk of thromboembolic events, including pulmonary embolisms and other blood clots, though he says the increase is not dramatic. They may also experience erectile dysfunction and loss of libido. Combined with fewer treatment options, these side effects have led many men to stop before completing 5 years of endocrine therapy.

According to Leone, addressing this problem is twofold. Clinicians need to explain why endocrine therapy is important, and the field needs to expand the options available to men through efforts such as ETHAN. With more options, clinicians could try another endocrine therapy when side effects arise instead of stopping endocrine therapy altogether.


Related to this article